Completed
A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir Dihydroxypropoxymethyl Guanine DHPG Treatment of Symptomatic Central Nervous System CNS Congenital Cytomegalovirus CMV Infections.
Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2010-08-27
130
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the benefits and safety of the antiviral drug ganciclovir (DHPG) given intravenously to treat newborn infants who are born infected with cytomegalovirus (CMV). CMV is a herpes virus that can infect most organs of the body, resulting in death in 10-30% of babies with symptoms of CMV. It can cause severe brain damage in a large percentage of surviving babies. Children in this study have a CMV infection of the central nervous system (CNS).
CONDITIONS
Brief Title
A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here